Companies are encouraged to contact our Industry team as early as possible, even before applying for NIHR CSP, particularly for help with identifying new investigators and sites.
Commercially sponsored studies can use NIHR CSP if they have been adopted onto the NIHR CRN Portfolio. If a study has not been adopted prior to applying for NIHR CSP, the Industry team will contact the company upon receipt of a validated Portfolio Application Form, in order to start the feasibility and adoption process.
To create a study ID and use NIHR CSP, the research team should:
- Complete and submit a Portfolio Application Form through the Integrated Research Application System (IRAS)
- This form is created when the answer to Project Filter question 3a is England and question 5a is No and 5b is Yes.
The Sponsor will be emailed within two working days, and asked for submission of the R&D application through IRAS. The R&D application will be validated. The Lead CLRN, which is usually where the Chief Investigator is based will facilitate the CSP process and act as a central point of contact during the governance review.
The research team will be requested to complete and submit a Site Specific Information (SSI) application for each NHS organisation in England that is taking part in the study. These should be submitted through IRAS to the CLRN of which the NHS organisation is a member.
- Receipt of the Protocol will trigger the adoption review process by either the Comprehensive Clinical Research Network, the Primary Care Research Network or one of the six Topic-specific Clinical Research Networks
- Receipt of the R&D application will enable the study-wide governance review to commence
- Receipt of the SSI applications means the local governance review can start for a particular site.
Research can start at a site when the Sponsor receives the Letter of NHS Permission from that site.
